All News

male female

Do different genders experience PsA differently?

Olga Petryna, MD

There has been a lot of talk lately about the difference in the way male and female PsA patients experience their disease.  Are the differences only cultural or are there important clinical differences in the disease presentation, organ involvement and complications that physicians should be aware of?   

Read Article
syringe,needle,vaccine

Vaccine Efficacy in Patients with Seronegative Spondyloarthritis

Catherine Sims, MD

Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.

Read Article
ACR Best

ACR Best Abstracts - Day 2

Jack Cush, MD

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.

Here are the RheumNow faculty selections for #ACRbest abstracts today:

Read Article
artificial intelligence machine learning computer

Can Neural Networks Answer Important Diagnostic Dilemmas in Rheumatology?

Olga Petryna, MD

An interesting study presented at ACR22 looked at whether neural networks can distinguish seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) using hand MRI data based on the structural inflammation patterns.

Read Article
Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcomes sustained. No joint difference to ADA, skin slightly better @RheumNow #ACR22 Abstr#L02 https://t.co/RjCV8Hb3HR https://t.co/a0NQFyFZlt

Links:

Richard Conway RichardPAConway ( View Tweet)
A new murine model to study Pso and PsA! Immunodeficient mice NSG-SGM3 🐁 injected w/ serum & PBMCs from Pso and/or PsA pts = pro & arthritis (same phenotype than pts) Mice skin & synovia >effector memory CD8 T cell & < naïve https://t.co/cxSvEZC9Ly Abs#L04 #ACR22 @Rheumnow https://t.co/hfbtSsP3f8

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
#L02 #acr22 @rheumnow Bimekizumab ph3 in PsA: meaningful clinical improvement, improved mTSS, no new safety signals. Wk 52 ACR50: 53.0% PBO/BKZ, 54.5% BKZ, 50.0% ADA; MDA 53.7% PBO/BKZ, 55.0% BKZ, 52.9% ADA . mTSS change from baseline ≤0.5): 87.3% PBO/BKZ, 89.3% BKZ, 94.1% ADA https://t.co/NYRrPUBjt1
Olga Petryna DrPetryna ( View Tweet)
BE OPTIMAL: BKZ in PsA Phase 3 RCT Data at 52 wks 700+ completed study ACR50: 53% PBO/BKZ, 54% BKZ, 50% ADA PASI 100 65% PBO/BKZ, 61% BKZ, 48% ADA No Rx progression 87% PBO/BKZ, 89% BKZ, 94% ADA Candida infections 7% BKZ, 0.7% ADA https://t.co/MMjN1Aa3qf Abs#L02 #ACR22 @Rheumnow https://t.co/keF0QOZMwA

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Get the skinny on Bimmy! Gotta learn this name #Bimekizumab in bio naive PsA N=852 Bimmy=IL17 A & F inhibitor Great data on skin & joints. Where will it fit in as we have other IL17Ai’s is IL17F giving added value? #ACR22 #ACRBest @RheumNow https://t.co/wNAzTaLhsM
Janet Pope Janetbirdope ( View Tweet)
Does tofacitinib work better in patients with PsA and AS who smoke? Abstract #1036 #ACR22 @RheumNow 🚬519 ever smokers 🚭767 never smokers 💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO ✋Overall, efficacy was generally comparable in ever v. never 🚬

Catherine Sims, MD DrCassySims ( View Tweet)

Here's the 1 year model #ACR22 @RheumNow https://t.co/VhEuJMMyIt
Richard Conway RichardPAConway ( View Tweet)
Eder et al. New PRESTO prediction model for PsA development in PsO. 1 year and 5 year models presented @RheumNow #ACR22 Abstr#1612 https://t.co/xMMVaIGnN5 https://t.co/RlJ3ZlEeDE

Links:

Richard Conway RichardPAConway ( View Tweet)
FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to benefit from TYK2i deucravacitinib @RheumNow #ACR22 Abstr#2133 https://t.co/eVq4XQgX5l https://t.co/HZlTS5OZ2s

Links:

Richard Conway RichardPAConway ( View Tweet)
Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on lab values other than increase in trigs. Guess this is why they don't have lab monitoring on label? @RheumNow #ACR22 Abstr#2132 https://t.co/ueIVKQc6jr https://t.co/u99QE71VQ5

Links:

Richard Conway RichardPAConway ( View Tweet)
Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safety signals seen. @RheumNow #ACR22 Abstr#2134 https://t.co/5SGKKrvwbc https://t.co/ynvfZiOrsp

Links:

Richard Conway RichardPAConway ( View Tweet)
⇧ brain functional connectivity to the insula between the mid-posterior IC & brain areas involved in sensory (thalamus), learning/affective (parahippocampal gyrus), cognitive (prefrontal cortex) pain modulation in PsA. Sunzini F Abs#2256 https://t.co/5TUcOacuIS #ACR22 @RheumNow https://t.co/7IqLYzzpyA

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Kavanaugh et al. TYK2i deucravacitinib in PsA. Nice breakdown of MDA and its components over 16 weeks. MDA achieved 23-24% with deucravacitinib at 16 weeks vs 8% with placebo @RheumNow #ACR22 Abstr#2136 https://t.co/9IG8CeZzMh https://t.co/Vg8E20y7Z8

Links:

Richard Conway RichardPAConway ( View Tweet)
Mease et al. TYK2i Deucravacitinib in PsA. Phase 2 RCT 52 week results. PASDAS, DAPSA efficacy maintained through week 52. No new safety concerns. @RheumNow #ACR22 Abstr#1598 https://t.co/sRKkgkYtQJ https://t.co/YMXMEH3wsq

Links:

Richard Conway RichardPAConway ( View Tweet)
Ogdie @AlexisOgdie et al. CorEvitas, PsA treatment after 1st line TNFi failure. Switching MOA probably more effective @RheumNow #ACR22 Abstr#1600 https://t.co/vy8gxDaYxZ https://t.co/NmkESbSNfL

Links:

Richard Conway RichardPAConway ( View Tweet)
@RheumNow video from #ACR22 Opioid use in PsA and SpA patients Discussing abstract 1012 by @AlexisOgdie https://t.co/fKRog1aIkH

Eric Dein ericdeinmd ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×